Trial · NCT04856930
Adverse events203
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 203
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | COVID-19 | Infections and infestations | Placebo-Controlled Period: Imsidolimab 400/200 mg | 4 | 50 | 4 |
| other | COVID-19 | Infections and infestations | Placebo-Controlled Period: Imsidolimab 200/100 mg | 3 | 50 | 3 |
| other | COVID-19 | Infections and infestations | Placebo-Controlled Period: Placebo | 3 | 49 | 3 |
| other | COVID-19 | Infections and infestations | Extension Period: Imsidolimab 400/200 mg | 2 | 40 | 2 |
| other | COVID-19 | Infections and infestations | Extension Period: Imsidolimab 200/100 mg | 3 | 42 | 3 |
| other | COVID-19 | Infections and infestations | Extension Period: Placebo to Imsidolimab 400/200 mg | 0 | 19 | 0 |
| other | COVID-19 | Infections and infestations | Extension Period: Placebo to Imsidolimab 200/100 mg | 3 | 21 | 3 |
| other | Hidradenitis | Skin and subcutaneous tissue disorders | Placebo-Controlled Period: Imsidolimab 400/200 mg | 1 | 50 | 1 |
| other | Hidradenitis | Skin and subcutaneous tissue disorders | Placebo-Controlled Period: Imsidolimab 200/100 mg | 3 | 50 | 3 |
| other | Hidradenitis | Skin and subcutaneous tissue disorders | Placebo-Controlled Period: Placebo | 4 | 49 | 6 |
| other | Hidradenitis | Skin and subcutaneous tissue disorders | Extension Period: Imsidolimab 400/200 mg | 3 | 40 | 4 |
| other | Hidradenitis | Skin and subcutaneous tissue disorders | Extension Period: Imsidolimab 200/100 mg | 2 | 42 | 2 |
| other | Hidradenitis | Skin and subcutaneous tissue disorders | Extension Period: Placebo to Imsidolimab 400/200 mg | 1 | 19 | 3 |
| other | Hidradenitis | Skin and subcutaneous tissue disorders | Extension Period: Placebo to Imsidolimab 200/100 mg | 0 | 21 | 0 |
| other | Nasopharyngitis | Infections and infestations | Placebo-Controlled Period: Imsidolimab 400/200 mg | 0 | 50 | 0 |
| other | Nasopharyngitis | Infections and infestations | Placebo-Controlled Period: Imsidolimab 200/100 mg | 0 | 50 | 0 |
| other | Nasopharyngitis | Infections and infestations | Placebo-Controlled Period: Placebo | 3 | 49 | 3 |
| other | Nasopharyngitis | Infections and infestations | Extension Period: Imsidolimab 400/200 mg | 1 | 40 | 1 |
| other | Nasopharyngitis | Infections and infestations | Extension Period: Imsidolimab 200/100 mg | 3 | 42 | 3 |
| other | Nasopharyngitis | Infections and infestations | Extension Period: Placebo to Imsidolimab 400/200 mg | 1 | 19 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04856930/events